This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Marcantonio, D. Articles by Malspeis, L. Search for Related Content PubMed PubMed Citation Articles by Marcantonio, D. Articles by Malspeis, L.

2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a Novel Chloroethylnitrosourea Analogue with Enhanced Antitumor Activity against Human Glioma Xenografts¹

Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada H3T 1E2 [D. M., L. C. P.]; Developmental Therapeutics Program, Division of Cancer Treatment, Diagnosis, and Centers, National Cancer Institute, Frederick Cancer Research and Development Center, Frederick, Maryland 21701-8527 [M. G. H., M. C. A., R. F. C., E. A. S., L. M.]; and Southern Research Institute, Birmingham, Alabama 35205 [D. J. D., C. A. C.]

Nitrosoureas are among the most widely used agents used in the treatment of malignant gliomas. Here, the activity of 2-chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) was compared with that of 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU), in vivo against s.c. implanted SF-295 and U-251 central nervous system (CNS) tumor xenografts. When given i.v., q4d for 3 doses, to athymic mice bearing s.c. SF-295 tumors, SarCNU, at an optimum of 167 mg/kg/dose, produced 9 tumor-free animals of 10 total animals, 1 regression, and no evidence of overt toxicity (20% body weight loss). With a similar dosing schedule, BCNU produced no tumor-free animals, six regressions, and one drug-related death at its optimum of 30 mg/kg/dose. Furthermore, SarCNU retained high antitumor activity at two lower dose levels, 66 and 45% of the optimal dose, whereas BCNU demonstrated a progressive loss of antitumor activity at lower doses. Following p.o. administration, SarCNU similarly demonstrated antitumor activity that was superior to that of BCNU. In the U-251 CNS tumor model, SarCNU yielded six of six tumor-free animals at 80 mg/kg/dose with i.p. administration q.d. for 5 days, starting on day 14, whereas BCNU, at 9 mg/kg/dose, yielded three of six tumor-free mice and one drug-related death. Again, SarCNU resulted in tumor-free animals at 66 and 45% of its optimal dose and was relatively nontoxic, in contrast to BCNU. Results of testing to date indicate that SarCNU is clearly more effective than BCNU against the human CNS tumors SF-295 and U-251 in vivo. These results encourage the initiation of clinical trials for SarCNU, in an effort to improve therapeutic approaches to glioma, but clinical trials must determine whether superiority of SarCNU in preclinical models can be extrapolated to patients.

¹ This work was supported by National Cancer Institute Contracts N01-CM-47000 and N01-CM-57207.

² To whom requests for reprints should be addressed, at Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, 3755 Côte Ste. Catherine, Montreal, Quebec, Canada H3T 1E2. Phone: (514) 340-8260 ext. 5528; Fax: (514) 340-8302.

Received 4/29/97. Accepted 7/31/97.

This article has been cited by other articles:

				D. E. Post, N. S. Devi, Z. Li, D. J. Brat, B. Kaur, A. Nicholson, J. J. Olson, Z. Zhang, and E. G. Van Meir Cancer Therapy with a Replicating Oncolytic Adenovirus Targeting the Hypoxic Microenvironment of Tumors Clin. Cancer Res., December 15, 2004; 10(24): 8603 - 8612. [Abstract] [Full Text] [PDF]

				L. Panasci, S.F. Stinson, D. Melnychuk, V. Sandor, W.H. Miller Jr, G. Batist, F. Patenaude, N. Bangash, L. Panarello, M. Alaoui-Jamali, et al. SarCNU, a Nitrosourea Analog on a Day 1, 5, and 9 Oral Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid Tumors J. Clin. Oncol., January 15, 2003; 21(2): 232 - 240. [Abstract] [Full Text] [PDF]

				Z.-P. Chen, Z.-M. Wang, C. A. Carter, M. C. Alley, G. Mohr, and L. C. Panasci Both Extraneuronal Monoamine Transporter and O6-Methylguanine-DNA Methyltransferase Expression Influence the Antitumor Efficacy of 2-Chloroethyl-3-sarcosinamide- 1-nitrosourea in Human Tumor Xenografts J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 712 - 715. [Abstract] [Full Text]

				Z.-P. Chen, J. Remack, T. P. Brent, G. Mohr, and L. C. Panasci Extraneuronal Monoamine Transporter Expression and DNA Repair Vis-a-Vis 2-Chloroethyl-3-sarcosinamide-1-nitrosourea Cytotoxicity in Human Tumor Cell Lines Clin. Cancer Res., December 1, 1999; 5(12): 4186 - 4190. [Abstract] [Full Text] [PDF]